CLINILABS APPOINTS CHIEF OPERATING OFFICER
– Clinilabs, Inc. announced today that Ms. Lorraine Marchand has been appointed as the Company’s new Chief Operating Officer. As the COO of Clinilabs, Ms. Marchand will be responsible for the Company’s operations and the implementation of its strategic development plans.
Ms. Marchand has more than 20 years experience in pharmaceutical drug development, and her track record includes the successful management and expansion of global clinical research business units. Ms. Marchand’s experience includes the development and management of global teams in both the public and private sectors of healthcare. She has led several initiatives resulting in reductions in drug development cycle time while at the same time reducing costs and process inefficiencies.
“We are delighted to welcome Ms. Marchand to our senior management team,” stated Dr. Gary Zammit, President & CEO of Clinilabs. “We look forward to the contributions that she will make as we widen our reputation as a premier provider of clinical drug development services. Ms. Marchand’s experience undoubtedly will serve the needs of our clients, and contribute to our ability to deliver value on a larger scale.”
At her most recent position at Covance, Inc., a contract research organization (CRO), Ms. Marchand served as the Vice President of Late Stage Development Services. Previously, she held the position of Executive Director of Global Clinical Development at Bristol-Myers Squibb (BMS), a pharmaceutical company.
Ms. Marchand received a BS degree from the University of Maryland, and received the degree of MA in Journalism and Public Affairs at the American University, Washington, DC. She received Master of Business Administration degrees from the Columbia University Business School in New York City and the London Business School.
Contact:
Jeanine M. Estrada
212-981-2716
jestrada@clinilabs.com |
